cannabis
cannabis · page 2
- Opinion
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
Written by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma.
- Industry Trends
Manufactured Optimism: Why Trump Can’t ‘Just Wave a Magic Wand’ and Reschedule Cannabis
There is a frustrating misimpression circulating in the cannabis community regarding rescheduling.
- UK & Europe
No EU Monograph for Cannabis Flowers Over ‘Lack of Evidence’ as New GACP Rules Loom
The Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA) published a draft opinion on July 09, open for consultation between 1 August and 31 October 2025, which concludes that no EU monograph can currently be created for Cannabis sativa L., flos.
- Your #1 Podcast on Cannabis News
What Cannabis Leaders Can Learn from Olympic Champions
In this special edition of the Business of Cannabis Podcast, Tim Kirby, CEO of Releaf, sits down with Professor Chris Shambrook, renowned performance psychologist and long-time advisor to the British Olympic rowing team.
- Opinion
Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage
In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar.
- Cultivation
Overwhelming Majority (80%) of Canadian Cannabis Now Sourced from Legal Distributors in Major Turnaround
Nearly 80% of Canadian’s now source their cannabis solely from the legal market, marking a stark shift away from the illicit market seven years after legalisation.
- Public Markets
Cannabis Stocks Hit Highest Point This Year on Trump Rescheduling Hopes
Cannabis stocks across North America have skyrocketed to their highest point so far this year, despite a lukewarm promise from the US President on cannabis rescheduling.
- Uncategorized
‘GMP Is the Foundation of Trust in Our Industry’ – Inside Linnea’s Take on Pharma-Grade Cannabinoids
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
- Medical Cannabis
German Health Insurance Companies No Longer Want to Cover the Costs of Cannabis Flower
In Germany, the partial legalisation of cannabis has opened up a new telemedicine market. Instead of visiting a doctor in person, patients can now request prescriptions online, with cannabis flowers sent directly to patients via specialist pharmacies.
- US & Canada
Cannabis Groundhog Day: Trump’s Rescheduling Talk Fuels Familiar Hype Cycle
The cannabis industry is once again awash with hope and speculation over the promise of rescheduling following reports that President Trump has promised the industry that ‘it’s something we’re going to look at’.
- Legal Analysis
Seizures of Cannabis Smuggled Into Germany Have Risen 50% Despite Reforms
You can also read this story in German, here. When the Cannabis Act came into force in Germany, the aim was to improve the country’s drug policy by changing the way the popular recreational drug was handled.
- Retail & Brands
New York Cannabis Regulator’s ‘Catastrophic’ Blunder Threatens Over 100 Businesses
Over 100 legal New York cannabis dispensaries could be forced to relocate following a monumental blunder from the state’s Office of Cannabis Management (OCM).
